Trial reportScientific reports2026
Comparative effectiveness of levofloxacin versus third-generation cephalosporins and predictors of treatment outcomes in upper respiratory tract scleroma: a tertiary center experience.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upper respiratory tract scleroma is a chronic granulomatous disease that primarily affects the nose but may involve any part of the upper respiratory tract. The mainstay of treatment is prolonged antibiotic therapy. This prospective comparative study included 90 adults with upper respiratory tract scleroma treated at Minia University Hospital, Egypt, between September 2024 and August 2025. Patients were randomly allocated into two equal groups using closed sealed opaque envelopes to receive levofloxacin or third-generation cephalosporins for three months. The mean age was 36.3 ± 10.4 years, and 90% were females. Nasal obstruction (96.7%) and nasal crustation (90%) were the most common manifestations. Rhinolaryngoscleroma was diagnosed in 86.7% of patients, whereas 13.3% had rhinoscleroma. Clinical improvement was significantly higher with levofloxacin than with third-generation cephalosporins (80% vs. 60%, P = 0.038). In the multivariable analysis, treatment type and pharyngeal involvement remained significant predictors of clinical improvement. Levofloxacin treatment was associated with higher odds of improvement (OR = 5.8, P = 0.015). These findings highlight the importance of early diagnosis and appropriate antibiotic selection in the management of upper respiratory tract scleroma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.